Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from August 17, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on November 15, 2025.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted
$82.68 Published $91.73 Target $92.13 Window close $94.27 Peak
$80.01 – $82.90Entry zone — fair-value band
$82.68Published — price the day we called it
$91.73Target — the price the thesis aimed for
$94.27Peak — highest point inside the window, not a realized return
$92.13Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 88 days.

Peak price
$94.27
peak on November 14, 2025 — not a realized return
Peak gain
+14%
peak, from the publication price
Window close
$92.13
end-of-window price, context only
Days to target
88
Window
August 17, 2025 – November 15, 2025

The thesis — published August 17, 2025

Predicted growth
+13%
over the measurement window
Target price
$91.73
the price the thesis aimed for
Entry zone
$80.01 – $82.90
the fair-value band we waited for
Price at publication
$82.68
published August 17, 2025
Confidence
72%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Merck mixes steady income with growth. Fresh success in an important bladder cancer study on Aug 17 backs its leadership in cancer drugs. The stock also pays about a 4.1% dividend, which helps returns during quieter periods. Recent trading shows healthy interest and a positive trend, so buying small dips makes sense. Over the next few months, trial wins and income could keep shares drifting upward, though the price still reacts to valuation headlines.

Primary drivers

  • Strong trial results for KEYNOTE-905 in bladder cancer boost confidence
  • Price trend looks healthy, with lots more buyers than usual recently
  • A roughly 4.1% dividend pays investors while they wait for growth
  • Cancer medicine portfolio offers steady, defensive growth potential

How it played out

MRK: target reached in 88 days

On Aug. 17, Lyra published a short-term MRK thesis at $82.68. It expected 13% growth, with a target of $91.73. The thesis pointed to KEYNOTE-905 bladder cancer study results, a healthy price trend, a roughly 4.1% dividend, and Merck's cancer medicine portfolio as the setup.

Inside the window, MRK reached the target in 88 days. The stock peaked at $94.27 on Nov. 14, above the $91.73 target, with a 14% gain. It ended the window at $92.13. The published thesis played out.

What happened during the window

On Oct. 30, 2025, Merck reported third-quarter sales of $17.28 billion and adjusted earnings of $2.58 per share, according to Investor's Business Daily. The same report said Merck raised its 2025 profit guidance and narrowed its sales outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals